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Abstract Muir-Torre syndrome (MTS) is a rare can-
cer-predisposing syndrome that is autosomal domi-
nantly inherited and characterized by the development
of sebaceous skin lesions (adenomas, epitheliomas,
basaliomas and carcinomas). These lesions are typi-
cally associated with tumors that belong to the spec-
trum of hereditary nonpolyposis colorectal cancer
(HNPCC) (i.e. tumors of the colorectum, endome-
trium, stomach or ovary). Biliary malignancy in asso-
ciation with MTS has only rarely been reported. We
report a case of Muir-Torre syndrome associated with
intrahepatic cholangiocarcinoma, a location not previ-
ously described, and associated with a novel missense
mutation of the MSH2 gene (c.2026T > C), predicted
to disrupt the function of the gene.
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CEA carcino embryonic antigen
HNPCC hereditary non polyposis colon cancer
MTS Muir-Torre syndrome
MRI magnetic resonance imaging
MSI microsatellite instability
Introduction
Muir-Torre syndrome (MTS) is a rare autosomal-
dominant cancer-predisposing syndrome, first described
in the 1960s [1, 2]. MTS is characterized by the associ-
ation of sebaceous skin lesions (adenomas, epithelio-
mas, basaliomas and carcinomas) or keratoacanthomas
and one or more visceral tumors that belong to the
spectrum of HNPCC (i.e tumors of the colon and
rectum, endometrium, stomach, ovary, biliary tree) [3,
4]. Molecular studies have documented microsatellite
instability in both skin and visceral tumors [5], linked
to inactivation of a mismatch repair protein, as a result
of a germline defect in either the MLH1 or the MSH2
gene [6, 7].
Biliary malignancy in association with MTS has only
rarely been reported [8] and our observation of MTS
associated with primary cholangiocarcinoma of the
liver is, to our knowledge, the first to be described as a
consequence of a missense mutation of the MSH2 gene.
The clinical manifestations, rapid evolution to meta-
static disease and the localization of the metastases are
shown to be atypical for HNPCC.
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Case report
A 41-year-old Caucasian female presented to our sur-
gery department with a firm and asymptomatic mass of
the upper right quadrant, noticed about 3 weeks be-
fore. No other complaint was mentioned except mul-
tiple nodules of the skin. Two of these nodules located
in the right and left retro-auricular area have recently
emerged. One nodule was dark and located in the right
temporal scalp and the other nodules were yellow and
were located on the face. The patient had two polyps of
the colon resected 4 years and 1 year before, respec-
tively. The polyps were located in the transverse colon
and were surgically removed by segmental transverse
colectomy. Pathological diagnoses were tubulovillous
adenoma with foci of high grade dysplasia and villous
adenoma with high grade dysplasia, respectively. No
invasive features were observed in these two adeno-
mas. Besides, at the age of 39 an endometrial polyp had
been discovered at a gynecologic control. Radiological
investigations were carried out with a thoraco-
abdominal CT-SCAN and a hepatic MRI. Both
showed a very large tumor, occupying almost all the
right liver. Laboratory investigations revealed a carci-
noembryonic antigen (CEA) increased to 983 ng/ml
(normal value 0–6 ng/ml).
Pre-operative endoscopy of the gastrointestinal tract
and pelvic CT-SCAN was undertaken to rule out a
primary carcinoma. A right liver lobectomy (segments
IV–VIII) was performed. Surgical specimen weighted
4,250 kg. The tumor measured 22 cm of maximal
diameter and presented with a whitish and fleshy as-
pect and in some parts with a gelatinous consistence
(Fig. 1). There was no other nodule in the remaining
hepatic lobe. Microscopic examination showed a
mucinous adenocarcinoma. In the absence of any pri-
mary extrahepatic tumor, the final pathological diag-
nosis was a primary mucinous cholangiocarcinoma of
the liver. Biopsies of the cutaneous nodules of the face
indicated that the right and left retro-auricular nodules
corresponded to metastasis of a mucinous adenocarci-
noma whereas the nodule of the scalp corresponded to
a sebaceous epithelioma. The other nodules of the face
were not biopsied but were clinically suggestive of
sebaceous hyperplasia or sebaceous adenomas. Family
history indicated that the patient’s mother had three
metachronous colon cancers at the age of 44, 62 and
63 years, a cancer of the uterus at 62 years, and a
cancer of the ureter at 70 years (Fig. 2). She had no
lesions of the skin.
Considering family history and the fact that tumors
of the colon, the scalp, the uterine corpus and the
biliary tract in a young patient, are suggestive of the
HNPCC tumor spectrum, we searched for microsatel-
lite instability in the tumors of the colon and in the
cholangiocarcinoma. The reference panel of five mi-
crosatellites (BAT25, BAT26, D5S346, D2S123 and
D17S250) was used, based on recommendations of the
National Cancer Institute workshop on microsatellite
instability (MSI) [9]. The results indicated a MSI-high
status for each tumor. The immunohistochemical
staining revealed a loss of nuclear expression, in both
hepatic tumor and colonic adenomas, of MSH2 and
MSH6 proteins, whereas the expression of MLH1 and
PMS2 proteins was preserved (Fig. 3). Final patho-
logical diagnosis of the hepatic tumor was primary
mucinous cholangiocarcinoma and a Muir-Torre syn-
drome was suggested.
After obtaining the patient’s written informed con-
sent, a peripheral blood sample was taken to perform
analysis of the MSH2 gene from genomic DNA. Bidi-
rectional sequencing of exons and introns/exons junc-
tions of the MSH2 gene (Genebank UO4045) was
performed after PCR amplification of genomic DNA.
This showed a c.2026T > C transition which is pre-
dicted to result in replacement of a serine amino acid
by a proline at position 676 (p.S676P) of the MSH2
protein. A serine has been particularly conserved
during evolution at this position, from bacterial to
human species. Furthermore, this amino-acid is located
in the ATP-binding domain and its replacement by a
Fig. 1 Macroscopic feature of a hepatic cholangiocarcinoma
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proline is incompatible with an alpha-helix structure.
Besides, the replacement of the lysine in the adjacent
position 675 is clearly pathogenic [10]. Thus, the
modification of the structure of the MSH2 protein
containing the S676P alteration is predicted to impair
the function of the gene. Nevertheless, formal confir-
mation of the pathogenicity can only be brought by
functional studies. Analysis by Multiplex Ligation-
dependent Probe Amplification (MLPA) did not show
any MSH2 anomaly. Besides, the MSH2 gene has now
been entirely screened for mutations in 157 patients
suspected of HNPCC, residing in Switzerland. As the
MSH2 c.2026T > C change was not found among 314
chromosomes from these individuals, it is unlikely to
be a variant present in the Swiss population. The
absence of the MSH2 protein in the hepatic cholan-
giocarcinoma strongly supports its causative role in the
development of this tumor.
Ten months after her initial admission, the patient
was re-hospitalized because of persistent headache.
CT-SCAN and MRI of the head reveals two brain
metastases which were surgically resected and histo-
logically assessed as metastasis of mucinous adeno-
carcinoma.
Fig. 2 Pedigree of the
probant’s family: Ca:
carcinoma; Ad: adenoma
Fig. 3 Immunostaining of a
hepatic cholangiocarcinoma
showing normal expression of
the MLH1 and PMS2 protein
genes (a, b) and loss of
expression of MSH2 and
MSH6 protein genes (c, d)
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Discussion
MTS, a clinical variant of HNPCC syndrome, has
rarely been associated with tumors of the biliary tree.
Except the primary carcinoma of the ampulla of Vater
originally described by Torre [2], to our knowledge no
other case of biliary tumors has been reported in MTS
[3, 8]. Considering the spectrum of tumors seen in the
HNPCC syndrome, biliary tract is still a rare location,
accounting for far less than 10% of all locations [11].
Mecklin et al. [12] reported 11 cases of tumors of the
biliary tract or the papilla of Vater representing 4% of
all tumors distribution among 315 patients in families
with HNPCC. The sex distribution was 5 men and 6
women and the mean age was nearly the same for both
sexes: 59 years. The location of the tumor was as fol-
lows: 1 intrahepatic, 6 common bile duct and 4 ampulla
of Vater.
Sporadic cholangiocarcinomas account for 3% of all
gastrointestinal cancers and 60–70% arise at the
bifurcation of the hepatic ducts (Klatskin tumors) and
20–30% in the distal common bile duct. About 5–10%
of cholangiocarcinomas are peripheral, arising within
intrahepatic ducts of the liver parenchyma itself, and
correspond to the second commonest hepatic tumor.
Known risk factors account for only a few cases of
cholangiocarcinomas and seem to be associated with
chronic inflammation of the biliary epithelium (pri-
mary sclerosing cholangitis, parasitic infection, fibro-
polycystic liver disease, intrahepatic biliary stones,
chemical carcinogen exposure and viral hepatitis) [13].
None of those conditions were found out in our re-
ported case. More than 90% of cholangiocarcinomas
are usual adenocarcinomas whereas the important
mucinous production within the tumor is an uncom-
mon finding in intrahepatic cholangiocarcinomas [14].
Here we report a case of mucinous cholangiocarci-
noma in a background of MTS characterised by ade-
nomas of the right colon, polyp of the endometrium,
and sebaceous tumors. The possibility that the liver
tumor was a metastasis has been considered. However,
careful re-examination and re-sectioning of the two
colonic adenomas did not show any sign of invasive-
ness. Moreover, a pre-operative endoscopy of the
gastrointestinal tract did not reveal any additional tu-
mor, exploration of the urogenital system, including a
pelvic echography and breast examination were also
negative. Thus, we consider that the lesion observed in
the liver was a primary tumor. The case reported here
is of particular interest because the tumors of the
genital and digestive tracts were still benign, whilst the
hepatic cholangiocarcinoma was very aggressive with
development of cutaneous and cerebral metastases.
While the proportions of MLH1 and MSH2
mutations in HNPCC are almost equal, in MTS the
vast majority of germline mutations were identified
in MSH2 [7]. Most of the pathogenic mutations
identified in HNPCC are protein truncating muta-
tions, but the transition c.2026T > C, which we
identified in the MSH2 gene in our MTS patient, is a
missense mutation which has not been reported so
far in HNPCC patients.
Summary
In conclusion, we report an unusual case of Muir-Torre
syndrome, associated with primary mucinous cholan-
giocarcinoma of the liver, and we present evidence that
a novel germline mutation of the MSH2 gene is the
underlying cause of this severe cancer.
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